There's still time to REGISTER to attend the
#HCWGlobalInvestment2022
conference in-person at the Fontainebleau Hotel in
#MiamiBeach
May 23-26. Join us for keynote speakers, presenting companies, investor one-on-one meetings and networking opportunities:
The
#HCWCO
FinTech, Blockchain & Cryptocurrency
#investmentbanking
team has completed 25+ transactions for 2021 YTD, yielding a total transaction value of $3B+. View our recent transactions here:
We are initiating coverage of $XSPA, which is pivoting its spa business towards a more comprehensive travel
#healthandwellness
store model that includes medical testing and the sale of retail products. To view our focused coverage universe, click here:
#HCWCO
is initiating coverage on
@Progenity
($PROG), which primarily focuses on employing proprietary ingestible device technologies in tandem with the delivery of FDA approved therapies. Read more in the Morning Summary:
#NASH
#HealthcareInvestors
Our team recently participated in a Private Placement transaction for
@ArgoBlockchain
, a
#cryptocurrency
mining firm. See all of our recent transactions here:
The
#HCWCO
#FinTech
, Blockchain & Cryptocurrency equity research team is initiating coverage on
@DigimaxGlobal
($DIGI.CN), which is now focused on the artificial intelligence space. Read more in the Morning Summary:
Join us in-person in Miami Beach for the
#HCWCO
Global Investment Conference May 23-26. This event is also being offered virtually.
#InstitutionalInvestors
pre-register here:
We are initiating coverage of $ABUS, a company primarily focused on discovering, developing, and commercializing a portfolio of complementary assets for a potential cure for chronic hepatitis B virus (HBV) infection.
$AUTL has entered into an exclusive option and license agreement with Moderna ($MRNA; not rated), which gives Moderna access to up to 4 proprietary binders against immuno-oncology (I/O) targets that the company may then pair with its mRNA-based technology.
Our investment banking team recently acted as placement agent on a $40 million transaction for $XSPA. To view other
#lifesciences
transactions click here:
Recently, the
#HCWCO
Capital Markets team acted as Placement Agent on transactions for
@eurasiamining
($EUA) and
@FLUXpwr
($FLUX). View more transactions here:
The
#HCWCO
FinTech, Blockchain & Cryptocurrency
#investmentbanking
team has completed 25+ transactions for 2021 YTD, yielding a total transaction value of $2.5B+. View our recent transactions here:
#HCWCO
is initiating coverage of $COCP, a developer of small molecule antiviral drugs that utilizes its unique proprietary co-crystallization platform to design novel small molecules aimed at well-known molecular targets within multiple viruses. More here:
We are initiating coverage of
@PortageBiotech
($PRTG) which is developing an array of immuno-oncology strategies including a novel invariant natural killer T cell agonist, IMM60.
#BioTechInvestors
read more in the
#HCWCO
Morning Summary:
The countdown has begun. The HCW 23rd Annual Global Investment Conference held virtually begins in three days on September 13, 2021. Register for virtual one-on-one
#investormeetings
and
#investorpresentations
here:
#HCW23Global
We have a strong reputation as a proven intendant of client accounts and as a steadfast fiduciary. We've been able to maintain stability, and grow to transcend the limits of what was expected of the financial community. Here is to 150 years!
#HCWCO
@Kitov_Pharma
has changed its corporate name to Purple Biotech Ltd. and stock symbol to $PPBT. The change became effective December 22, 2020, on the
@NASDAQ
and Tel Aviv Stock Exchange (TASE). Read more in
#HCWCO
’s Morning Summary:
Community involvement is a cornerstone of our company culture. We are
#thankful
this Thursday for
@CityHarvest
. They are tackling
#foodwaste
to feed fellow New Yorkers.
#HCWCO
is initiating coverage of
@eSportsEntGroup
($GMBL) that currently operates in both
#esports
& online wagering verticals with the goal of providing a platform in which participants can play, watch, & bet on their favorite esports events. More:
We are initiating coverage on
@AcumenPharm
($ABOS) a clinical-stage company developing a novel disease-modifying approach to Alzheimer's disease. Details in the
#HCWCO
Morning Summary;
#BiopharmaInvestors
The
#HCWCO
investment banking team acted as placement agent on a $50 million transaction for $GEVO. View this and other recent
#Cleantech
transactions here:
$PHARM.AS announced that Ruconest received approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for use in pediatric patients (age 2+) for acute HAE attacks. See more in the
#HCWCO
Morning Report:
#HCWCO
is initiating coverage of
@Oncopeptides
, a specialty oncology company that is developing
#Melflufen
(melphalan flufenamide), a next-generation small molecule targeted chemotherapy agent aimed at blood cancers. For more, see our Morning Summary:
Our analysts discuss $SRPT ‘s news that indicate pre-clinical models indicate high levels of transduction in all muscles throughout the body with no adverse effects in today’s Morning Summary.
#lifesciences
#financialnews
We're excited to kick off our Global Life Sciences Conference this morning with over 450 presenting companies, investor meetings, and other virtual events through Wednesday. You can still register here:
#HCWCOEvents
#InstitutionalInvestors
#HCWCO
's Equity Research Team is initiating coverage of $HGEN, a healthcare company with lead asset Lenzilumab, an antibody targeting GM-CSF. Learn more
It's not too late to register for tomorrow's Psychedelics in Psychiatry and Beyond Virtual Conference. Register here for networking opportunities and company presentations:
#investorpresentations
#biopharma
Welcome to the start of the
#HCWCO
23rd Annual Global Investment Conference being held virtually today through September 15, 2021. Please tag your conference posts with
#HCW23Global
.
$AXSM announced that it has completed the patient randomization in the STRIDE-1 study, a Phase 3, randomized, double-blind, active-controlled trial of AXS-05 in patients with treatment-resistant depression. Details in our Morning Summary:
$ARWR announced an R&D and commercial collaboration with Takeda on ARO-AAT, which is in Phase 2/3 development for alpha one antitrypsin deficiency (AATD) with liver disease (AATLD). Details here:
#HCWCO
is initiating coverage of $OCGN, a clinical-stage company developing therapies for rare and under-served eye diseases. Learn more here:
#lifesciences
#healthcare
We recently participated in a $500 million transaction for $SRPT.
@Sarepta
is a
#biopharmaceutical
company primarily focused on rapidly advancing
#DMD
therapies. Learn more about this transaction here:
#HCWCO
Last chance to register! Tomorrow begins the
#HCWCO
23rd Annual Global Investment Conference, September 13-15, 2021. Ensure you're ready by reviewing panel and webcast information here:
#InstitutionalInvestors
#HCW23Global
We are initiating coverage of
@ArteloBio
($ARTL) which is focused on developing therapies in the treatment of cancer and for other unmet treatment needs. More here:
#HealthcareInvestors
Our FinTech, Blockchain & Cryptocurrency equity research team is initiating coverage of
@BiggDigitalCo
($BIGG .CN) which operates a leading Canadian crypto trading platform in Netcoins & a crypto forensics software business. Details here:
#CryptoInvestor
We are initiating coverage of
@Context_Tx
($CNTX) a clinical stage
#biotech
company focused on developing small molecules and immunotherapy for the treatment of women's cancers. More in the
#HCWCO
Morning Summary:
@Oncopeptides
($ONCO.ST) announced that the
#FDA
granted Priority Review for Melflufen in combination with Dexamethasone for the treatment of adult patients with multiple myeloma. More in today’s
#HCWCO
Morning Summary:
Our annual
#NASH
Investor conference on Monday, October 21 will feature presentations from $AGN, $ALT, $CBAY, $DBRX, and $NDRA along with other public and privately held companies in the NASH space. Register here:
This week, the
#HCWCO
research team initiated coverage on
@Targovax
, whose lead asset is ONCOS-102, an oncolytic virus with dual activity in both direct killing of tumor cells, and inducing innate and adaptive immune activation.
$KPTI announced that the
@US_FDA
approved Xpovio, in combination with Velcade (bortezomib) and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Learn more here:
#HCWCO
is a full-service Healthcare-focused
#investmentbank
with some 100 dedicated professionals, including 12 Ph.D.'s across investment banking and equity research. Get to know us:
The
#HCWCO
#EquityResearch
team is initiating coverage on $PSTV, a clinical-stage oncology company developing novel therapies against brain cancer. Review our coverage universe here:
#lifesciences
#buyside
$AUPH announced that the
@US_FDA
approved LUPKYNIS (voclosporin) to treat lupus nephritis patients in combination with a background immunosuppressive therapy regime. Read more in
#HCWCO
's Morning Summary:
#biopharma
#HCWCO
offers deep sector expertise with 100 sector dedicated professionals, including more than a dozen with Ph.D.’s, and has one of the largest
#equityresearch
coverage footprints focused on
#healthcare
and
#lifesciences
sector.
We are always looking for highly motivated, committed, qualified, and talented people, who will actively shape our company’s success.
#investmentbanking